Skip to main content
TipRanks
Go Ultimate75% OFF

Mega Genomics Limited (6667) Stock Price & Analysis

0 Followers

6667 Stock Chart & Stats

HK$6.46-HK$0.33(-4.86%)
At close: 4:00 PM GMT+8
HK$6.5HK$6.75HK$7HK$7.25Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 6.46 - HKD 6.69
52-Week Range
HKD 4.80 - HKD 7.53
Previous Close
HKD 6.79
Volume
N/A
Average Volume (3M)
84.74K
Market Cap
HKD 1.52B
Enterprise Value
HKD 995.76M
Total Cash (Recent Filing)
HKD 424.49M
Total Debt (Recent Filing)
HKD 28.52M
Price to Earnings (P/E)
46.2
Beta
-0.18
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
N/A
Dividend Yield
2.63%

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet

Very low leverage and a substantial equity base provide financial resilience and flexibility. This structure can help the company withstand operating volatility, fund initiatives without excessive borrowing, and preserve strategic options over the next several quarters.

Strong Recent Revenue Growth

Rapid recent revenue expansion indicates improving commercial scale and demand relative to the prior year. If maintained, a larger revenue base can support operating leverage, broaden market reach, and provide more resources for continued business development.

Historical Cash-generation Capability

Although the latest year was weak, prior substantial operating cash generation shows the business has produced cash under more favorable conditions. That historical capability provides a foundation for recovery if cash conversion stabilizes and supports internally funded growth.

Bears Say

Negative Latest-year Cash Flow

Negative operating and free cash flow despite accounting profit signals weak recent cash conversion. Persistent outflows could reduce internally available funding, increase reliance on the strong balance sheet, and constrain investment or shareholder-return capacity.

Margin And Earnings Compression

Material margin contraction means additional revenue is currently producing less profit than in earlier peak years. The decline in net income despite higher sales raises concerns about earnings quality and limits the durability of reported top-line growth.

Low Returns And Earnings Cyclicality

Modest returns on a large equity base indicate that capital is not currently generating strong profitability. Combined with the prior annual loss, this points to earnings cyclicality that may make results less predictable and weaken compounding potential.

Mega Genomics Limited News

6667 FAQ

What was Mega Genomics Limited’s price range in the past 12 months?
Mega Genomics Limited lowest stock price was HK$4.80 and its highest was HK$7.53 in the past 12 months.
What is Mega Genomics Limited’s market cap?
Mega Genomics Limited’s market cap is HK$1.52B.
When is Mega Genomics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Mega Genomics Limited’s earnings last quarter?
Mega Genomics Limited released its earnings results on Aug 31, 2026. The company reported HK$0.138 earnings per share for the quarter.
Is Mega Genomics Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Mega Genomics Limited pay dividends?
Mega Genomics Limited pays a dividend of HK$0.17 which represents an annual dividend yield of 2.63%. See more information on Mega Genomics Limited dividends here
What is Mega Genomics Limited’s EPS estimate?
Mega Genomics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mega Genomics Limited have?
Mega Genomics Limited has 224,300,200 shares outstanding.
What happened to Mega Genomics Limited’s price movement after its last earnings report?
Mega Genomics Limited reported an EPS of HK$0.138 in its last earnings report. Following the earnings report the stock price went down -0.07%.
Which hedge fund is a major shareholder of Mega Genomics Limited?
Currently, no hedge funds are holding shares in HK:6667
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology